

November 5, 2018

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Unaudited Financial Results for the quarter and half year ended September 30, 2018

Pursuant to Regulation 33 Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Unaudited Financial Results for the quarter and half year ended September 30, 2018 which were approved by the Board of Directors of the Company, at its meeting held on November 5, 2018 along with Limited Review Report issued by the Statutory Auditors of the Company.

The meeting commenced at 12:00 noon and concluded at 3:00 p.m.

Kindly take the above on your record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited


Rajesh Shirambekar
Head – Legal & Company Secretary



Encl: As above

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited review report on unaudited quarterly financial results and unaudited year-to-date financial results of RPG Life Sciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of RPG Life Sciences Limited

We have reviewed the accompanying statement of unaudited financial results of RPG Life Sciences Limited ('the Company') for the quarter ended 30 September 2018 and the year-to-date results for the period from 1 April 2018 to 30 September 2018 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').


This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants

Firm's Registration No: 101248W/W-100022



Bhavesh Dhupelia

Partner

Membership No: 042070

Mumbai
5 November 2018

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2018 (Rs. in Lakhs)						
Particulars	Quarter ended			Six months ended		Year ended
	30-09-2018	30-06-2018	30-09-2017	30-09-2018	30-09-2017	31-03-2018
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	9,050	7,989	8,951	17,039	16,802	34,714
2 Other Income	6	39	6	45	15	98
3 Total Income	9,056	8,028	8,957	17,084	16,817	34,812
4 Expenses						
(a) Cost of Materials Consumed	1,194	1,511	1,247	2,705	2,790	7,195
(b) Purchases of Stock-in-Trade	957	1,215	1,050	2,172	2,056	4,935
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	1,126	(250)	796	876	617	(669)
(d) Excise Duty Paid on sale of goods	-	-	-	-	319	319
(e) Employee Benefits Expense	2,386	2,222	2,172	4,608	4,214	9,014
(f) Finance Costs	105	104	108	209	204	380
(g) Depreciation and Amortisation Expense	381	371	358	752	706	1,434
(h) Other Expenses	2,597	2,597	2,476	5,194	5,114	10,168
Total Expenses	8,746	7,770	8,207	16,516	16,020	32,776
5 Profit before tax	310	258	750	568	797	2,036
6 Income tax expenses:						
a. Current Tax	85	61	151	146	161	385
b. Deferred Tax	9	14	(32)	23	(38)	306
7 Profit for the period	216	183	631	399	674	1,345
8 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	(6)	(6)	(23)	(12)	(46)	(22)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	2	2	-	4	-	8
Other Comprehensive Income Net of Tax	(4)	(4)	(23)	(8)	(46)	(14)
9 Total Comprehensive Income for the period	212	179	608	391	628	1,331
10 Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323	1,323
11 Other Equity						14,152
12 Earnings per Share (of Rs. 8 each) (not annualised):						
(a) Basic	1.31	1.11	3.82	2.41	4.08	8.13
(b) Diluted	1.31	1.11	3.82	2.41	4.08	8.13


Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 05, 2018. The Statutory Auditors of the Company have conducted a 'Limited Review' of the results for the quarter and six months ended September 30, 2018.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- The Government of India introduced the Goods and Services Tax (GST) with effect from 1st July 2017, consequently revenue from operations for the quarters ended 30th September 2018, 30th September 2017 and 30th June 2018, for six months ended 30th September 2018 is net of GST. However revenue for all other periods presented is inclusive of excise duty, where applicable. The Net Revenue from operations (Net of GST/ Excise Duty) as applicable are stated below:

Particulars	Quarter ended			Six months ended		Year ended
	30-09-2018	30-06-2018	30-09-2017	30-09-2018	30-09-2017	31-03-2018
Revenue from Operations	9,050	7,989	8,951	17,039	16,802	34,714
Less: Excise Duty	-	-	-	-	319	319
Net Revenue from operations	9,050	7,989	8,951	17,039	16,483	34,395

- Effective April 1, 2018, the Company has adopted Ind AS 115 'Revenue from contracts with customers'. Based on the assessment done by the management, there is no material impact on the revenue recognised during the period.

For RPG Life Sciences Limited


 Yugal Sikri
 Managing Director
 Mumbai, November 05, 2018



Statement of Standalone Assets and Liabilities as at September 30, 2018

(Rs. in Lakhs)

Particulars	As at 30th September 2018	As at 31st March 2018
	(Unaudited)	(Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	8,367	7,994
Capital work-in-progress	145	480
Other intangible assets	4,814	5,086
Intangible assets under development	437	393
Financial assets		
i. Loans	8	9
ii. Other financial assets	30	28
Current Tax asset (Net)	62	57
Deferred tax assets (Net)	694	744
Other non-current assets	151	74
Total non-current assets	14,708	14,865
Current assets		
Inventories	4,686	5,369
Financial assets		
i. Trade receivables	5,903	6,813
ii. Cash and cash equivalents	52	11
iii. Bank balances other than (ii) above	38	83
iv. Other financial assets	131	110
Other current assets	1,460	1,876
Total current assets	12,270	14,262
Total assets	26,978	29,127
EQUITY AND LIABILITIES		
Equity		
Equity share capital	1,323	1,323
Other equity		
Reserves and Surplus	14,064	14,152
Total equity	15,387	15,475
LIABILITIES		
Non-current liabilities		
Financial liabilities		
i. Borrowings	731	1,023
ii. Other financial liabilities	299	279
Provisions	279	279
Total non-current liabilities	1,309	1,581
Current liabilities		
Financial liabilities		
i. Borrowings	3,936	3,792
ii. Trade payables	3,505	5,187
iii. Other financial liabilities	1,242	1,503
Provisions	1,147	1,225
Current tax liabilities (Net)	-	20
Other current liabilities	452	344
Total current liabilities	10,282	12,071
Total liabilities	11,591	13,652
Total equity and liabilities	26,978	29,127

